Navigation Links
Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
Date:3/15/2011

essful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory app
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... May 11, 2011 Chimerix, Inc., a pharmaceutical ... showing that the majority of immunocompromised patients with ... lead antiviral compound, CMX001, had a > 99% ... two weeks of therapy.  These CMX001 clinical data, ...
... AUSTIN, Texas, May 11, 2011 HCB Health, one ... the nation and the leading healthcare agency in the ... campaign in the 22nd annual Manny Awards, a national ... was presented for a consumer campaign supporting Sound Surgical ...
Cached Medicine Technology:CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection 2CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection 3HCB Health Wins Manny Award for Best Medical Device Campaign 2
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... , ALEXANDRIA, Va., Oct. 7 Catholic Charities USA ... assessment and response team to American Samoa to assist ... coordinate with FEMA and other agencies in providing relief ... of the earthquake and tsunami devastation. , (Logo: ...
... Ancient Hamar Tribe Adopts Sustainable Hygiene and Water Programs ... ISLAND, Wash., Oct. 7 Northwest-based nonprofit Global Team ... grant by US Agency for International Development (USAID) to ... in Ethiopia. Since 2008, GTLI, which incubated a ...
... PRXL ) will release First Quarter Fiscal Year 2010 financial ... stock market. The announcement will be available on PAREXEL,s website ... website at www.prnewswire.com . , PAREXEL will host ... Wednesday, October 28, 2009 to discuss the results. To access ...
... This press release is available in French ... tourism in Latin America needs to be regulated to ... new study published in the journal Developing World ... marketing themselves to international health care consumers: these clinics ...
... are helping, but more is needed to stem teen obesity, ... in the United States are becoming healthier places thanks to ... still more is needed to combat teen obesity, a series ... studies, which appear in a September supplement to the ...
... The Ensign Group, Inc. (Nasdaq: ENSG ), announced ... facilities, South Valley Care Center in West Jordan, a ... Care Center in Provo, and Castle Country Care Center ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , "These strategic ...
Cached Medicine News:Health News:Catholic Charities USA Moves Disaster Response Team to American Samoa 2Health News:Global Team for Local Initiatives Awarded $387,000 by USAID: New Model for Indigenous Health in Ethiopia 2Health News:PAREXEL Announces Date of First Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Health News:Study examines ethical dilemmas of medical tourism 2Health News:Nutrition Still Not 'A' Grade in U.S. Schools: Studies 2Health News:The Ensign Group Acquires Three Utah Skilled Nursing Facilities 2
... system builds on the basic infrastructure ... in the system are networked to ... Windows® operating system, which monitors system ... personal computer, RoamAlert Integrity provides reporting ...
... Awarix provides an enterprise visibility ... throughput, improve caregiver effectiveness, and increase ... edge RFID location systems and geospatial ... systems to create a real time ...
MONOJECT MAGELLAN Safety Blood Collection Needle...
This is adapted to microplate or card....
Medicine Products: